Loading clinical trials...
Loading clinical trials...
To compare the incidence of lymphocele in Endometrial cancer patients with thrombin gel matrix used and not used during pelvic lymph node dissection.
Pelvic lymph node dissection is the most accurate staging tool to determine lymph node involvement in endometrial cancer. Lymphoceles developed after surgery can cause serious morbidity, additional costs and delays in chemotherapy or radiotherapy. In this study, conventional pelvic lymphadenectomy will be compared with thrombin gel matrix application after pelvic lymphadenectomy. Our goal is to prospectively assess the lymphostatic effect of thrombin gel matrix in endometrial cancer patients undergoing pelvic lymph node dissection.
Age
18 - 90 years
Sex
FEMALE
Healthy Volunteers
No
Kocaeli University
Kocaeli, Turkey (Türkiye)
Start Date
December 20, 2019
Primary Completion Date
July 1, 2020
Completion Date
July 2, 2020
Last Updated
July 7, 2020
72
ACTUAL participants
Thrombi-Gel
DRUG
Conventional Pelvic lymphadenectomy
PROCEDURE
Lead Sponsor
Kocaeli University
NCT07318727
NCT05036681
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06976333